Century Therapeutics (IPSC) PT Slashed to $4 at Piper Sandler Following Termination of the Bristol-Myers Alliance
Tweet Send to a Friend
Piper Sandler analyst Edward Tenthoff lowered the price target on Century Therapeutics (NASDAQ: IPSC) to $4.00 (from $12.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
